Profound Medical (PROF)
(Delayed Data from NSDQ)
$8.21 USD
+0.56 (7.32%)
Updated May 14, 2024 04:00 PM ET
After-Market: $8.25 +0.04 (0.49%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PROF 8.21 +0.56(7.32%)
Will PROF be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PROF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PROF
ElectroCore, Inc. (ECOR) Reports Q1 Loss, Tops Revenue Estimates
Profound Medical (PROF), Siemens Unite to Treat Prostate Cancer
PROF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
Profound Medical (PROF) Soars 9.4%: Is Further Upside Left in the Stock?
How Much Upside is Left in Profound Medical (PROF)? Wall Street Analysts Think 66.06%
Other News for PROF
Profound Medical gets FDA okay for TULSA AI module
Profound Medical’s AI Tool Streamlines Prostate Therapy
Profound Medical Receives U.S. FDA 510(k) Clearance for ‘Contouring Assistant’ AI Module that Enables Creation of an Automated TULSA Treatment Plan
Profound Medical’s AI Tool Gets FDA Nod
Profound Medical receives FDA clearance for 'contouring assistant' AI module